Cythera Bio is developing interaction-mediated technologies to mitigate the biological impact of microplastics and nanoplastics. Our work focuses on reducing particle interaction with biological systems through aggregation, sequestration, and modulation of downstream inflammatory pathways, with applications spanning wellness products and longer-term therapeutic development.

 

The company is led by Melinda B. Chu, M.D., M.B.A., a physician-scientist and inventor with extensive experience translating laboratory concepts into practical solutions. Dr. Chu is a Princeton University alum and holds an M.D. from Saint Louis University and an Executive M.B.A. from Washington University Olin Business School. She has led more than 14 pharmaceutical-sponsored clinical trials and investigator-initiated studies, giving her deep expertise in regulatory strategy, experimental design, and translational research. She is the inventor on multiple patent families and has authored over 50 technical papers across environmental monitoring, water intelligence, and exposure-related technologies.

​

Cythera Bio’s scientific efforts are supported by team members and key collaborators, Ryan Logan, Ph.D. and Stefan Tekel, Ph.D.

 

The company is actively exploring partnerships with organizations developing next-generation wellness, exposure-support, and therapeutic solutions.